WO2025168022 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN (HTT)
National phase entry is expected:
Publication Number
WO/2025/168022
Publication Date
14.08.2025
International Application No.
PCT/CN2025/076099
International Filing Date
07.02.2025
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN (HTT)
[French]
COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE HUNTINGTINE (HTT)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
ZHANG, Yongquan
Priority Data
PCT/CN2024/076668
07.02.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4784 | |
| EPO | Filing, Examination, Granting | 70133 | |
| Japan | Filing, Examination, Granting | 4135 | |
| South Korea | Filing, Examination, Granting | 6227 | |
| USA | Filing, Examination, Granting | 22490 |
Total:
107,769
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of HTT gene and for treatment of HTT-associated diseases and conditions are provided. Provided are HTT dsRNA agents, HTT antisense polynucleotide agents, compositions comprising HTT dsRNA agents, and compositions comprising HTT antisense polynucleotide agents that can be used to reduce HTT expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène HTT et pour le traitement de maladies et d'états associés à HTT. L'invention concerne des agents ARNdb HTT, des agents polynucléotidiques antisens HTT, des compositions comprenant des agents ARNdb HTT, et des compositions comprenant des agents polynucléotidiques antisens HTT qui peuvent être utilisés pour réduire l'expression de HTT chez des cellules et des sujets.